Novo Nordisk's $2.1 Billion Bet on Inflammation Just Went Up in Smoke
Novo Nordisk killed two cardiovascular trials of ziltivekimab after an independent committee said they were unlikely to succeed. The $2.1 billion Corvidia acquisition now looks like one of the most expensive dead ends in recent pharma history, and it leaves Novo scrambling to diversify beyond its GLP-1 empire.
The Most Expensive Bonfire in Copenhagen
In 2020, Novo Nordisk wrote a check for $725 million upfront to acquire a small biotech called Corvidia Therapeutics. The total deal could have reached $2.1 billion with milestones. The prize: a single drug called ziltivekimab, an anti-inflammatory antibody that Novo believed could crack open a massive new market in cardiovascular disease.
Six years later, that bet is looking like a very expensive lesson in humility.
On September 4, Novo Nordisk told investigators it was pulling the plug on two of its three remaining cardiovascular trials of ziltivekimab, called HERMES and ATHENA. An independent data monitoring committee reviewed the evidence and concluded something no pharma company wants to hear: these trials were unlikely to succeed.
The news landed publicly on September 7, and the fallout is more than just a clinical disappointment. It strikes at the heart of Novo's strategy to become more than just the GLP-1 company.
A Drug That Could Lower Inflammation but Couldn't Save Hearts
To understand why this hurts, you need to understand the idea behind ziltivekimab.
For decades, heart disease treatment focused almost entirely on cholesterol. Statins became the backbone of cardiology. But researchers noticed something frustrating: even patients with perfectly controlled cholesterol kept having heart attacks. Something else was going on.
The leading theory? Chronic inflammation. Think of your arteries like pipes. Cholesterol is the gunk that builds up inside them, but inflammation is the rust that weakens the pipe walls and makes them crack. Targeting inflammation, the theory goes, could prevent the cracks even when the gunk is under control.
Ziltivekimab was designed to do exactly that. It's a monoclonal antibody (a lab-made protein) that blocks a molecule called IL-6, one of the body's key inflammatory signals. In early trials, it worked beautifully at the biomarker level: patients saw dramatic drops in (a marker of systemic inflammation), fibrinogen, and other indicators that scream "your body is inflamed."
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
hsCRP
The problem? Lowering those markers didn't actually stop people from having heart attacks, strokes, or dying from cardiovascular causes.
It's like having a smoke detector that you can silence without putting out the fire. The alarm stops, but the house is still burning.
ZEUS: The Trial That Started the Unraveling
The first major crack appeared with ZEUS, a large outcomes trial testing ziltivekimab in patients who had atherosclerotic cardiovascular disease (plaque buildup in arteries), chronic kidney disease, and elevated inflammation.
ZEUS was supposed to be the moment ziltivekimab proved itself. It was designed to show that the drug could reduce major cardiovascular events: heart attacks, strokes, cardiovascular death. Instead, it missed its primary endpoint. The inflammatory markers went down, but the events kept happening at roughly the same rate.
That failure should have been a five-alarm warning. Novo Nordisk, though, initially decided to keep HERMES and ATHENA running. Perhaps different patient populations or longer follow-up would tell a different story.
They didn't get the chance to find out. The independent monitoring committee looked at the totality of the data, including the ZEUS failure, and recommended stopping both trials. The math just wasn't there.
To make matters worse, reports have surfaced that ziltivekimab was also associated with higher rates of serious infections. That's not surprising when you think about it; IL-6 is part of your immune system's defense network. Blocking it reduces inflammation, but it also leaves the door open for infections. It's the same trade-off seen with other drugs that suppress parts of the immune system.
The Anti-Inflammatory Dream Isn't Dead, but It's on Life Support
Ziltivekimab's failure doesn't invalidate the entire anti-inflammatory hypothesis in cardiology. But it does narrow the path considerably.
The hypothesis got its biggest validation in 2017 with the landmark CANTOS trial. That study used canakinumab, an antibody targeting a different inflammatory molecule called IL-1β, in patients with prior heart attacks and high inflammation. The 150 mg dose reduced the combined risk of heart attack, stroke, or cardiovascular death by about 15%, and it did so without touching cholesterol levels. For the first time, the world had hard proof that fighting inflammation could prevent cardiac events.
But CANTOS came with baggage. Canakinumab was linked to higher rates of fatal infection, which made doctors and regulators nervous about the risk-benefit balance. Novartis filed a supplemental Biologics License Application for a cardiovascular approval for canakinumab, but the FDA issued a Complete Response Letter rejecting it.
Then came colchicine, a cheap, old anti-inflammatory drug. The COLCOT trial in 2019 showed that low-dose colchicine after a heart attack reduced future ischemic events. It was a less targeted approach, but it worked, and its low cost made it practical.
Ziltivekimab was supposed to be the next chapter: a more precise anti-inflammatory tool, targeting IL-6 specifically, without the fatal infection signal of canakinumab. Instead, it missed on efficacy and still raised safety concerns about infections.
The scorecard now reads: one drug (canakinumab) that worked but was too dangerous to market for cardiology; one drug (colchicine) that works modestly and is dirt cheap; and one drug (ziltivekimab) that didn't work at all for cardiovascular outcomes. The inflammation theory is real, but translating it into a blockbuster drug remains maddeningly elusive.
Novo's Diversification Problem Gets Louder
This is where the story shifts from science to strategy.
Novo Nordisk is, right now, one of the most valuable pharmaceutical companies on the planet. Its GLP-1 drugs, Ozempic and Wegovy, have turned it into a titan of the obesity and diabetes markets. But Wall Street has a question that grows louder every quarter: what else do you have?
Ziltivekimab was supposed to be a big part of the answer. When Novo acquired Corvidia, the company's R&D leadership described it as a cornerstone of their ambition to launch at least one product in atherosclerotic cardiovascular disease or heart failure between 2024 and 2028. The cardiovascular market is enormous, and Novo wanted a seat at the table that didn't depend on semaglutide.
Now, two of the three ziltivekimab cardiovascular trials are dead. Pharmaphorum described it as increasing pressure on Novo to license or acquire assets outside its obesity and diabetes comfort zone.
Analysts are taking notice. Jefferies called the outcome strategically negative because it removes a credible non-obesity growth opportunity, even though the near-term financial impact is small. Deutsche Bank reportedly views ziltivekimab as "effectively out of the picture." Novo kept its 2026 adjusted operating profit outlook unchanged, but the company will take a non-cash impairment charge from the discontinued trials.
The stock reaction, according to CNBC, looked disproportionate to the financial impact. But that's because the market isn't pricing in lost revenue from ziltivekimab; it's pricing in lost optionality. Every time Novo loses a non-GLP-1 asset, the company becomes more dependent on a single drug class. And single-drug-class companies make investors nervous, no matter how big that class is.
What's Left in the Cabinet?
Novo isn't bare. Its broader cardiovascular pipeline includes ocedurenone for uncontrolled hypertension and heart failure with preserved ejection fraction, an anti-ANGPTL3 antibody for dyslipidemia (high cholesterol), and PRX004 for a form of cardiac amyloidosis. The company has also made deals, including the Cardior acquisition and the acquisition of ocedurenone from KBP Biosciences, to fill gaps.
But none of these assets are as far along or as high-profile as ziltivekimab was. And the pressure to deliver a meaningful non-semaglutide win before the end of the decade just got significantly heavier.
The Bigger Lesson
Pharmaceutical history is littered with drugs that hit the right biomarkers but failed to help patients. It's one of the cruelest realities of drug development: biology is messy, and a lab number moving in the right direction doesn't guarantee that people live longer or healthier lives.
Ziltivekimab crushed inflammatory biomarkers. It engaged its biological target perfectly. And it still didn't work where it mattered most.
For Novo Nordisk, the question now is whether ARTEMIS can salvage anything, or whether the company needs to go shopping for its cardiovascular future. For the broader field, the lesson is more philosophical: knowing that inflammation drives heart disease is one thing. Knowing exactly how to stop it, safely and effectively, is something the industry clearly hasn't figured out yet.
The fire is real. We just can't find the right extinguisher.
4 min read
The Injection That Could Replace Your Blood Draws
The FDA just approved a weekly injection that could replace regular blood-draining procedures for patients with a rare blood cancer. Rusfertide's Phase 3 data crushed placebo, and the broad label has analysts buzzing about Protagonist Therapeutics' peptide platform.
